Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Introduction: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) represents a major clinical challenge and is fatal in most patients. Recently Schmitz et al (J ClinOncol 2016), defined an effective risk model, the CNS-IPI, to identify those at highest risk of CNS relapse,...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2016-12, Vol.128 (22), p.1855-1855
Main Authors: Phillips, Elizabeth H, Kirkwood, Amy A, Lawrie, Anthony, Rule, Simon, Patmore, Russell, Pettengell, Ruth, Burton, Cathy H, Ardeshna, Kirit M, Montoto, Silvia, Paneesha, Shankaranarayana, Smith, Paul, Wanek, Katharina, Clifton-Hadley, Laura, Linch, David C., McMillan, Andrew
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) represents a major clinical challenge and is fatal in most patients. Recently Schmitz et al (J ClinOncol 2016), defined an effective risk model, the CNS-IPI, to identify those at highest risk of CNS relapse, based on the international prognostic index (IPI) score and presence of renal or adrenal involvement. For DLBCL patients receiving R-CHOP-like regimens +/- intrathecal methotrexate, the risk of CNS relapse for low, intermediate and high-risk patients was
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V128.22.1855.1855